Development of a validated Western blot method for quantification of human dystrophin protein used in Phase II and III clinical trials of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) (P5.105)

Fj Schnell,S Lewis,Js Charleston,De Frank,S Wilton,Lr Rodino-Klapac,Jr Mendell,Z Sahenk,C Donoghue,J Dworzak

doi:10.1212/wnl.88.16_supplement.p5.105

Development of a validated Western blot method for quantification of human dystrophin protein used in Phase II and III clinical trials of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) (P5.105)

Fj Schnell, S Lewis + Show 8 more

https://doi.org/10.1212/wnl.88.16_supplement.p5.105

Copy DOI

Export

Save

Cite

Journal: Neurology	Publication Date: Apr 18, 2017
Citations: 1

Affiliation: Sarepta Therapeutics (United States), Nationwide Children's Hospital, Murdoch University

#Treatment Of Duchenne Muscular Dystrophy #Duchenne Muscular Dystrophy #Method For Quantification Of Protein #Quantification Of Protein #Human Protein #Human Dystrophin #Western Blot Method #Dystrophin Protein #Method For Quantification #Muscular Dystrophy

Abstract
Full-Text
Similar Papers

Abstract

Listen

Development of a validated Western blot method for quantification of human dystrophin protein used in Phase II and III clinical trials of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) (P5.105)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Neurology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Development of a validated Western blot method for quantification of human dystrophin protein used in Phase II and III clinical trials of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) (P5.105)